Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Zheng Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6582-847X; OpenAlex author ID A5100370673. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Editorial Expression of Concern: SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Co-author DOI 10.1007/s10620-026-10211-5↗
  2. SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Co-author DOI 10.1007/s10620-015-3759-9↗
  3. HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Co-author DOI 10.18632/oncotarget.2200↗
  4. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradat… Co-author DOI 10.3892/or.2014.3266↗
  5. [Down-regulated expression of PP2A catalytic subunit in pancreatic cancer cells promotes cell growth]. Co-author PMID 24721345↗
  6. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKα and sustained activation of the NF-κB pathway. First author DOI 10.1016/j.canlet.2011.02.009↗
  7. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathwa… First author DOI 10.1016/j.ejca.2011.08.014↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zekuan Xu · 7 shared papers, 2011–2026 · strength 0.56
  2. Yi Miao · 1 shared paper, 2026 · strength 0.33
  3. Yi Miao · 3 shared papers, 2011–2015 · strength 0.10
  4. Wěi Li · 2 shared papers, 2014–2015 · strength 0.10
  5. Min Tao · 3 shared papers, 2011–2014 · strength 0.09
  6. Daoming Li · 2 shared papers, 2011–2014 · strength 0.07
  7. Xiao Han · 2 shared papers, 2011 · strength 0.05
  8. Xin Xie · 1 shared paper, 2014 · strength 0.04
  9. Wei Li · 1 shared paper, 2014 · strength 0.04
  10. Mengyao Wu · 1 shared paper, 2014 · strength 0.04
  11. Guoxin Zhang · 1 shared paper, 2014 · strength 0.04
  12. Bin Wang · 1 shared paper, 2014 · strength 0.04
  13. Wenjie Zhang · 1 shared paper, 2014 · strength 0.04
  14. Jin Feng · 1 shared paper, 2014 · strength 0.04
  15. Wei Li · 1 shared paper, 2011 · strength 0.02
  16. Weiming Duan · 1 shared paper, 2011 · strength 0.02
  17. Kai Chen · 1 shared paper, 2011 · strength 0.02
  18. Wei Li · 1 shared paper, 2011 · strength 0.02
  19. Jingjing Zhang · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.